Haemovigilance

Platelets & Plasma

  • Cazenave JP.  Inactivation photochimique des pathogenes des plaquettes et du plasma:  cinq ans d’utilisation clinique de routine et d’hemovigilance.  Vers un changement de paradigme de la securite en transfusion.  Transfusion Clinique et Biologique 2011;18:53-61.
    > View abstract

Platelets

  • Cazenave J, Waller C, Mendel I et al.  Clinical experience with pathogen inactivation of platelet components for transfusion support.  Scharf RE (ed):  Progress and Challenges in Transfusion Medicine, Hemostasis and Hemotherapy.  Freiburg i.Br., Karger, 2008, pp 248-263.
    > View abstract
     
  • Cazenave JP, Isola H, Waller C et al.  Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center:  impact on patient outcomes and component utilization during a 3 year period.  Transfusion DOI:  10.1111.j.1537-2995.2010.02873.x
    > View abstract
     
  • Osselaer JC, Cazenave JP, Waller C et al.  An active hemovigilance program characterizing the safety profile of 7,437 platelet transfusions prepared with photochemical treatment.  Vox Sang 2008: 94;(4):315-323.
    > View abstract
     
  • Osselaer JC, Doyen C, Defoin L et al.  Universal adoption of photochemical treatment of platelet components:  impact on platelet and red cell component use.  Transfusion 2009;49:7:1412-22.
    > View abstract
     
  • Osselaer JC, Messe N, Hervig T et al.  A prospective observational cohort safety study of 5,106 platelet transfusions using components prepared with photochemical treatment.  Transfusion 2008;48(6):1061-71.
    > View abstract
     
  • Rasongles P, Angelini-Tibert MF, Simon P et al.  Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a chikungunya virus epidemic in Ile de la Reunion.  Transfusion 2009;49:6:1083-91.
    > View abstract
     
  • Schlenke P, Hagenah W, Irsch J et al.  Safety and Clinical Efficacy of Platelet Prepared Pathogen Inactivation in Routine Use for Thrombocytopenic Patients.  Annals of Hematology 2011;(Dec);90(12):1457-1465.
    > View abstract

Plasma

  • Cazenave JP, Waller C, Kientz D et al.  An active hemovigilance program characterizing the safety profile of 7,483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.  Transfusion 2010;50(6):1210-10.
    > View abstract
 
Untitled Document